Clinical trials
Small Cell Carcinoma clinical trials
Below are recruiting small cell carcinoma clinical trials, each written for real people, not researchers. We’re tracking 782 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06179069RecruitingPhase 1
Study of ZL-1310 for small cell lung cancer
This trial tests a new drug called ZL-1310, alone or with other treatments, for people with small cell lung cancer that has spread (extensive-stage). It aims to see if ZL-1310 can help shrink tumors or slow the disease.
Duarte, CaliforniaAges 18 years+ - NCT07874581Recruiting
Study of MRG003 for small cell lung cancer that has returned
This study tests a new drug, MRG003, for people with a type of lung cancer called small cell lung cancer that has spread or come back after earlier treatment. The goal is to see if this drug can help shrink tumors or slow the cancer's growth.
ShanghaiAges 18 years+ - NCT03288532RecruitingPhase 3
Adjuvant immunotherapy after kidney cancer surgery
This Phase 3 trial studies additional (adjuvant) treatment after kidney cancer surgery, to lower the chance the cancer comes back. It tests immunotherapy drugs (durvalumab and tremelimumab) in people whose scans show no visible remaining cancer after operation.
AberdeenAges 18 years+ - NCT04270591RecruitingPhase 1/Phase 2
Glumetinib for lung cancer with MET changes
This trial tests how well glumetinib works for non-small cell lung cancer (NSCLC) that has specific “MET” gene changes. It also checks safety and side effects, especially in people who can’t have surgery or have already had other treatments.
Louisville, KentuckyAges 18–80 - NCT05334277RecruitingPhase 2
Test furmonertinib for advanced EGFR-mutant lung cancer
This Phase 2 trial studies furmonertinib alone or with other treatment options to control advanced lung cancer that has specific EGFR gene changes. It may help by targeting the cancer-driving EGFR mutation, especially in people whose mutation is confirmed by a ctDNA blood test.
ChangchunAges 18 years+ - NCT04807140RecruitingPhase 2
Study of toripalimab before surgery for head and neck cancer
This trial tests toripalimab (an immunotherapy) given before surgery for untreated head and neck squamous cell carcinoma, either alone or with chemotherapy. The goal is to shrink or control the cancer earlier and see if it improves outcomes for people who plan curative surgery.
Guangzhou, GuangdongAges 18–80 - NCT05271916RecruitingPhase 1/Phase 2
New targeted drugs for advanced lung cancer with EGFR L858R
This study tests whether taking dacomitinib plus anlotinib as a first treatment can shrink or control advanced lung cancer that has the EGFR L858R mutation. It may help people who have not had any standard drug treatment yet, especially if their brain metastases are stable.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05623267RecruitingPhase 2/Phase 3
SugeMalimab after lung radiation and chemotherapy for limited-stage SCLC
This trial tests sugemalimab as “extra treatment” after standard chemoradiation for limited-stage small cell lung cancer. It aims to lower the chance of the cancer coming back by helping the immune system stay active after initial therapy.
Guangzhou, GuangdongAges 18 years+ - NCT05777278RecruitingPhase 1/Phase 2
Savolitinib plus docetaxel for advanced lung cancer with high MET
This trial studies savolitinib (an oral MET-targeted medicine) combined with docetaxel (an IV chemotherapy) in people with advanced non-small cell lung cancer (NSCLC) whose tumor has high MET activity. It’s designed to see if this combination can shrink tumors or control the cancer after the first standard treatment.
Guangzhou, GuangdongAges 18 years+ - NCT06080776RecruitingPhase 3
SH-1028 vs placebo for early-stage EGFR-mutated lung cancer
This trial tests a pill called SH-1028 (an EGFR-targeted drug) versus a placebo to see if it helps prevent lung cancer from coming back after surgery in people with EGFR-mutated NSCLC. You may be eligible if you had complete removal of stage II-IIIB NSCLC and your tumor has a specific EGFR mutation.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05997719Recruiting
Study of EGFR-mutated lung cancer evolution and markers
This study looks at how EGFR-mutated lung cancer changes over time and tries to find markers that can predict how well you might respond to treatment. You will provide a tumor sample for genetic analysis.
GuanzhouAges 18 years+ - NCT06125041RecruitingPhase 2
Adebelizumab with chemo and radiation for advanced lung cancer
This trial tests a new drug called Adebelizumab (an immunotherapy) combined with chemotherapy and radiation for people with extensive stage small cell lung cancer. The goal is to see if this combination helps shrink tumors and improves survival.
Jinan, ShandongAges 18–75 - NCT05011487RecruitingPhase 2
Before-surgery osimertinib plus chemotherapy for EGFR lung cancer
This study tests whether giving osimertinib together with chemotherapy before surgery can shrink and control EGFR-mutant, stage III lung cancer so it can be fully removed. If it works, it may improve the chances that the cancer does not come back after surgery.
Guangzhou, GuangdongAges 18–75 - NCT05382728RecruitingPhase 3
Test drug for EGFR-mutant lung cancer without prior treatment
This Phase 3 trial studies TY-9591 in people with locally advanced or metastatic non-small cell lung cancer (NSCLC) that has specific EGFR gene changes. It’s for those who haven’t had earlier medicines for advanced lung cancer, and it aims to see if the drug works better or safer than the comparison treatment.
Changsha, HunanAges 18–80 - NCT07863141RecruitingPhase 2
Maintenance therapy after first-line chemoimmunotherapy for advanced esophageal cancer
This study compares two maintenance treatments after initial chemotherapy plus immunotherapy for advanced esophageal squamous cell carcinoma. The goal is to see if adding anlotinib, a targeted drug that blocks blood vessel growth to tumors, to a PD-1 inhibitor is more effective than the PD-1 inhibitor alone.
Guangzhou, GuangdongAges 18–75 - NCT06194734RecruitingPhase 3
KC1036 vs. chemo for advanced esophageal cancer
This study compares a new drug, KC1036, to standard chemotherapy options for people with advanced esophageal squamous cell cancer that has progressed after immunotherapy and at least one chemo. It aims to see if KC1036 works better or has fewer side effects.
BeijingAges 18–75 - NCT06037733Recruiting
Focused radiation to main tumor after chemo-immunotherapy for lung cancer
This trial is for people with advanced non-small cell lung cancer whose tumors responded well to initial chemo-immunotherapy. Instead of giving full chest radiation, doctors will only target the main tumor to see if it can prevent regrowth with fewer side effects.
Wuhan, HubeiAges 18–75 - NCT06032052RecruitingPhase 2
Chemo plus immunotherapy for older adults with metastatic lung cancer
This trial tests a combination of chemotherapy and immunotherapy for people 65 or older with metastatic non-small cell lung cancer that has not been treated before and expresses PD-L1. It aims to see if this treatment can help control the cancer.
Wuhan, HubeiAges 65 years+ - NCT06020430Recruiting
Skipping routine radiation for advanced lung cancer after immunotherapy and chemo
This trial tests whether it is safe to skip routine radiation to the tumor bed in patients with stage III lung cancer that has responded well to immunotherapy and chemotherapy. It aims to reduce side effects while still controlling the cancer.
Wuhan, HubeiAges 18–75 - NCT05280314RecruitingPhase 2
Immunotherapy before and after surgery for stage III melanoma or throat cancer
This trial tests two immunotherapy medicines given before surgery and again after surgery to help control the cancer and improve outcomes. It studies people with resectable (operable) stage III melanoma or certain stage III/IVA throat cancers.
New Haven, ConnecticutAges 18 years+ - NCT06223711RecruitingPhase 2
Durvalumab with radiation therapy for limited-spread small cell lung cancer
This trial tests a combination of durvalumab (immunotherapy) plus radiation and chemotherapy for people with extensive-stage small cell lung cancer that has only a few distant spots. The goal is to see if this approach helps control the cancer better.
Augsburg, BavariaAges 18 years+ - NCT06445881RecruitingPhase 2
Herbal medicine for lung cancer before and after surgery
This trial is testing whether adding a traditional Chinese herbal formula (Modified Si Jun Zi Tang) to standard treatment before and after surgery can help people with early-stage non-small cell lung cancer. It aims to see if the herbs improve outcomes and reduce side effects.
Hangzhou, ZhejiangAges 18–75 - NCT07830342RecruitingPhase 1
Study of tumor-infiltrating lymphocyte therapy for advanced non-small cell lung cancer
This trial tests a new cell therapy that uses your own immune cells (TILs) to fight lung cancer. If you have advanced non-small cell lung cancer and standard treatments haven't worked, this treatment might help your immune system attack the cancer more effectively.
ShanghaiAges 18–75 - NCT06306456RecruitingPhase 1/Phase 2
GH21 combined with osimertinib for advanced lung cancer
This trial tests a new drug (GH21) combined with the targeted therapy osimertinib (Tagrisso) for people with advanced non-small cell lung cancer that has an EGFR mutation and has stopped responding to a similar treatment. The goal is to see if the combination can help when the cancer has progressed.
Hefei, AnhuiAges 18 years+
Hear when a new Small Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for small cell carcinoma?
- Yes. Clin2 currently lists 782 recruiting small cell carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a small cell carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a small cell carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.